(Q47312985)

13 January 2018

title

Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012-15. (English)

1 reference

13 January 2018

0 references

4

Shelley L Deeks

1 reference

13 January 2018

author name string

Tara Harris

series ordinal

1

1 reference

13 January 2018

Jyotsna Nair

series ordinal

2

1 reference

13 January 2018

Jill Fediurek

series ordinal

3

1 reference

13 January 2018

language of work or name

English

0 references

publication date

29 March 2017

1 reference

13 January 2018

published in

Vaccine

1 reference

13 January 2018

volume

35

1 reference

13 January 2018

issue

19

1 reference

13 January 2018

page(s)

2600-2604

1 reference

13 January 2018

Sex-based differences in immune function and responses to vaccination

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Adversomics: a new paradigm for vaccine safety and design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

The Xs and Y of immune responses to viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Sex-based biology and the rational design of influenza vaccination strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

A spot of bother: Why varicella vaccine programs matter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Assessing vaccine safety within Ontario's Universal Influenza Immunization Program, 2012-2013 to 2014-2015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Adversomics: the emerging field of vaccine adverse event immunogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Risk of anaphylaxis after vaccination in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Sex differences in injection site reactions with human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Incidence of Guillain-Barré syndrome in Alberta, Canada: an administrative data study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.03.035

10.1016/J.VACCINE.2017.03.035

7 January 2021

Identifiers

DOI

1 reference

13 January 2018

1 reference

13 January 2018